- Lectures / Webinars
- MOG-Antibody associated disease in children. Advances in diagnosis and treatment
MOG-Antibody associated disease in children. Advances in diagnosis and treatment
New
ICNTN Grand Rounds
Title: MOG-antibody associated disease in children: Advances in diagnosis and treatment
Speaker: Silvia Tenembaum
When: March 14, 2026
Time: 09:00 AM Eastern Time ( US/ Canada )
Click Here to Register
About the Topic:
The current availability of high-quality diagnostic tests (live cell-based assays, CBA) for the detection of serum autoantibodies directed against myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) has increased our capacity to identify and appropriately classify children and adults as having MOG-antibody associated disease (MOGAD), AQP4-IgG positive neuromyelitis optica spectrum disease (NMOSD), and rule out multiple sclerosis (MS). Relevant new information on MOGAD will be reviewed including the 2023 diagnostic criteria, the broad spectrum of presenting clinical phenotypes, and the neuroimaging diagnostic features for MOGAD and its main differential diagnoses. The talk will include recommendations for acute rescue therapy with special focus on the use of therapeutic plasma exchange in children. In addition, current knowledge on the use of relapse preventive therapies and its indication during the disease course will be discussed.
Pediatric neurologist and other healthcare providers treating acquired demyelinating disorders in the pediatric population are invited to join this session.
Learning objectives:
1- To increase their capacity to identify children and adolescents with MOGAD.
2- To rule out clinical and neuroimaging mimickers
3- To start early treatment interventions for full attack recovery
4- To define when relapse-preventive therapies should be used in pediatric patients with MOGAD
The current availability of high-quality diagnostic tests (live cell-based assays, CBA) for the detection of serum autoantibodies directed against myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) has increased our capacity to identify and appropriately classify children and adults as having MOG-antibody associated disease (MOGAD), AQP4-IgG positive neuromyelitis optica spectrum disease (NMOSD), and rule out multiple sclerosis (MS). Relevant new information on MOGAD will be reviewed including the 2023 diagnostic criteria, the broad spectrum of presenting clinical phenotypes, and the neuroimaging diagnostic features for MOGAD and its main differential diagnoses. The talk will include recommendations for acute rescue therapy with special focus on the use of therapeutic plasma exchange in children. In addition, current knowledge on the use of relapse preventive therapies and its indication during the disease course will be discussed.
Pediatric neurologist and other healthcare providers treating acquired demyelinating disorders in the pediatric population are invited to join this session.
Learning objectives:
1- To increase their capacity to identify children and adolescents with MOGAD.
2- To rule out clinical and neuroimaging mimickers
3- To start early treatment interventions for full attack recovery
4- To define when relapse-preventive therapies should be used in pediatric patients with MOGAD
Add comment